Xenon Pharmaceuticals (XENE) News and press releases

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $47

10 May 23

News, Price Target, Analyst Ratings

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $44 to $47.

Xenon Pharmaceuticals: Q1 Earnings Insights

9 May 23

Earnings

Xenon Pharmaceuticals Q1 EPS $(0.63) Misses $(0.62) Estimate

9 May 23

Earnings, News

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.62) by 1.61 percent. This is a 80 percent decrease over losses of $(0.35) per share

Earnings Scheduled For May 9, 2023

9 May 23

Earnings

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

Where Xenon Pharmaceuticals Stands With Analysts

25 Apr 23

Analyst Ratings

Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value

25 Apr 23

Biotech, News, Health Care, Price Target, Analyst Ratings, Trading Ideas, General

Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023

25 Apr 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Benzinga Pro's Top 5 Stocks To Watch For Tuesday, April 25, 2023: GM, SNAP, WEN, XENE, CXAI

25 Apr 23

Pre-Market Outlook

General Motors (GM) - Shares traded about 3% higher Tuesday morning following better-than-expected Q1 earnings and sales and raised guidance. The company said global deliveries of its automobiles

Cantor Fitzgerald Initiates Coverage On Xenon Pharmaceuticals with Overweight Rating, Announces Price Target of $58

25 Apr 23

News, Price Target, Initiation, Analyst Ratings

Cantor Fitzgerald analyst Charles Duncan initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight rating and announces Price Target of $58.

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $55

25 Apr 23

News, Price Target, Analyst Ratings

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $54 to $55.

Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $50 Price Target

21 Apr 23

News, Price Target, Reiteration, Analyst Ratings

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $50 price target.

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $51 Price Target

22 Mar 23

News, Price Target, Reiteration, Analyst Ratings

RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $51 price target.

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

6 Jun 23

News, Health Care, Press Releases

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs

Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

31 May 23

News, Press Releases

VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 Jefferies

Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference

11 May 23

News, Press Releases

VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2023 RBC

Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

9 May 23

Earnings, Press Releases

XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical trials

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023

3 May 23

News, Press Releases

VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the BofA

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

2 May 23

News, Press Releases

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and

Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

21 Apr 23

News, Health Care, Press Releases

BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the

Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

18 Apr 23

News, Press Releases

BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 22nd Annual

Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days

22 Mar 23

News, Press Releases

BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual Stifel